Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > BUSINESS
BUSINESS
- Takeda Terminates PIII Trial for AMG 479 for Pancreatic Cancer in Japan
August 10, 2012
- Up to 50% of Doctors Know About “Established Products” as Recognition Levels Rise: Pfizer Survey
August 9, 2012
- Mylan Transfers Exclusive Rights to Pfizer to Market EpiPen in Japan
August 9, 2012
- Shionogi’s Korean Partner Obtains Approval for Pirespa
August 9, 2012
- Astellas Applies for Irribow OD Tablet
August 9, 2012
- Ethical Drug Sales Down 0.3% in June: Crecon Report
August 8, 2012
- Hospira Files Additional Indication for Precedex for Non-Intubated Patients
August 8, 2012
- Daiichi Sankyo to Strengthen Cardiovascular Field by Comarketing Diabetes Treatments, Focusing on SGLT-2 Inhibitor
August 8, 2012
- 6 Listed Wholesalers Post Low Price Settlement Rates as of End-June, Showing Declines Compared to 2 Years Earlier
August 7, 2012
- Astellas to Close US Subsidiary for Urology Research
August 7, 2012
- Fuji Pharma to Acquire Thailand’s Largest Contract Manufacturer, to Make It Base of Overseas Operations
August 7, 2012
- Japan BCG Laboratory, Nippon Kayaku to Copromote Immunobladder
August 7, 2012
- Astellas to “Seek Every Opportunity” for Domestic Vaccine Business, Including Alliances with Foreign Companies
August 6, 2012
- Astellas’s Sales Down 3.3% in April-June Due to Competition with Generics
August 6, 2012
- Takeda to Exclusively Distribute 7 J&J OTC Brands in Japan
August 6, 2012
- Eisai’s April-June Sales, Profits Show Double-Digit Decrease by NHI Price Reduction of Aricept
August 6, 2012
- Sanofi Pasteur Not Planning to Follow Request to Cut IPV Price: President Triomphe
August 3, 2012
- Eisai: Domestic Sales of Aricept Down 6% on Volume Basis, to Target 90 Billion Yen through Patient Campaign
August 3, 2012
- Shionogi Files NDA for Lipodystrophy Treatment based on Data from Investigator-Initiated Trial
August 3, 2012
- DSP to Establish Sales Force for Anticancer Drugs in North America
August 3, 2012
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…